

# Sandra Philipp

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6903442/publications.pdf>

Version: 2024-02-01

27  
papers

1,144  
citations

471509

17  
h-index

642732

23  
g-index

43  
all docs

43  
docs citations

43  
times ranked

1548  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 594-603.	1.2	187
2	IL-19 Is a Component of the Pathogenetic IL-23/IL-17 Cascade in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2757-2767.	0.7	121
3	Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2017, 390, 40-49.	13.7	120
4	Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis. <i>JAMA Dermatology</i> , 2020, 156, 649.	4.1	120
5	S3 Guideline for the treatment of psoriasis vulgaris, update " Short version part 1 " Systemic treatment. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 645-669.	0.8	107
6	The genetic basis for most patients with pustular skin disease remains elusive. <i>British Journal of Dermatology</i> , 2018, 178, 740-748.	1.5	82
7	Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent. <i>BioDrugs</i> , 2018, 32, 397-404.	4.6	82
8	Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (6 to 17 years old): Results of the CADMUS Jr study. <i>British Journal of Dermatology</i> , 2020, 183, 664-672.	1.5	53
9	Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb INSIGHTFUL study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1876-1883.	2.4	36
10	S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 2 - Special patient populations and treatment situations. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 806-813.	0.8	32
11	Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study. <i>British Journal of Dermatology</i> , 2019, 181, 1177-1189.	1.5	28
12	The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder. <i>Expert Opinion on Therapeutic Targets</i> , 2006, 10, 817-831.	3.4	27
13	S3 Leitlinie zur Therapie der Psoriasis vulgaris Update " Kurzfassung Teil 1 " Systemische Therapie. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 645-670.	0.8	24
14	Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker " a retrospective multicenter study. <i>Journal of Dermatological Treatment</i> , 2021, 32, 878-882.	2.2	24
15	Combination of adalimumab with traditional systemic antipsoriatic drugs " a report of 39 cases. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 821-837.	0.8	20
16	Drug survival and reasons for drug discontinuation in palmoplantar pustulosis: a retrospective multicenter study. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 503-516.	0.8	20
17	Skin Sodium Accumulates in Psoriasis and Reflects Disease Severity. <i>Journal of Investigative Dermatology</i> , 2022, 142, 166-178.e8.	0.7	20
18	Application of Photoacoustic Methods and Confocal Microscopy for Monitoring of Therapeutic Response in Plaque Psoriasis. <i>Skin Pharmacology and Physiology</i> , 2018, 31, 308-315.	2.5	12

#	ARTICLE	IF	CITATIONS
19	Fluorescence optical imaging for the detection of potential psoriatic arthritis in comparison to musculoskeletal ultrasound. JDDG - Journal of the German Society of Dermatology, 2019, 17, 913-921.	0.8	9
20	A comprehensive, tri-national, cross-sectional analysis of characteristics and impact of pruritus in psoriasis. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 2064-2075.	2.4	8
21	S3-Leitlinie zur Therapie der Psoriasis vulgaris Update - Kurzfassung Teil 2 - Besondere Patientengruppen und spezielle Behandlungssituationen. JDDG - Journal of the German Society of Dermatology, 2018, 16, 806-814.	0.8	4
22	Neuroimmunological links in dermatology: psoriasis as a model disease in stress research. Expert Review of Dermatology, 2012, 7, 367-375.	0.3	3
23	Skin manifestations associated with chronic recurrent multifocal osteomyelitis in a 9-year-old girl. Journal of the American Academy of Dermatology, 2014, 71, e218-e219.	1.2	2
24	Plaque psoriasis. , 2014, , 55-75.		1
25	Erythrodermic psoriasis. , 2014, , 81-83.		0
26	Response to "Psoriasis patients"™ preference for an aerosol foam topical formulation"™ by Vender R et al .. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e401-e402.	2.4	0
27	Abstract P236: Sodium Accumulates in the Skin of Patients and Mice With Psoriasis. Hypertension, 2018, 72, .	2.7	0